Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) — Long-term Investment Intensity
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) has a Long-term Investment Intensity of 11.3% as of September 2019. Long-term investments of €852.93 Million represent 11.3% of total assets of €7.55 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See 2TZ total equity for net asset value and shareholders' equity analysis.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Long-term Investment Intensity (2013–2018)
This chart shows how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's Long-term Investment Intensity has evolved across 6 annual periods from 2013 to 2018. As of September 2019, the intensity stands at 11.3%, reflecting long-term investments of €852.93 Million against total assets of €7.55 Billion EUR. Also explore total assets of Tianjin Zhong Xin Pharmaceutical Group C for the complete picture of this company's asset base.
Annual Long-term Investment Intensity for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2018)
The table below presents the year-by-year Long-term Investment Intensity for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited from 2013 to 2018, covering 6 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see 2TZ market cap.
| Year | LT Investment Intensity | LT Investments (EUR) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2018 | 10.9% | €773.01 Million | €7.11 Billion | ▼ -0.3 pp |
| 2017 | 11.2% | €742.49 Million | €6.62 Billion | ▼ -7.3 pp |
| 2016 | 18.5% | €1.18 Billion | €6.36 Billion | ▲ +4.7 pp |
| 2015 | 13.8% | €835.72 Million | €6.07 Billion | ▼ -2.1 pp |
| 2014 | 15.8% | €861.55 Million | €5.44 Billion | ▼ -0.5 pp |
| 2013 | 16.3% | €859.60 Million | €5.26 Billion | — |